Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25589887 | 0.88 | GLP1R (0.42) | GLP1RSYKCCKBR | |
| SCHEMBL25589888 | 0.82 | GLP1R (0.40) | GLP1RCCKBR | |
| SCHEMBL18264750 | 0.80 | DPP4 (0.50) | DPP4DPP8DPP9GLO1CCKBR | |
| SCHEMBL13818496 | 0.80 | CA2 (0.42) | DPP4DPP8DPP9GLP1RCA2 | |
| SCHEMBL24891111 | 0.80 | GLP1R (0.63) | GLP1RSYKCCKBR | |
| SCHEMBL16421610 | 0.79 | DPP4 (0.38) | DPP4DPP8DPP9GLP1R | |
| SCHEMBL17985751 | 0.79 | SYK (0.46) | CA2SYK | |
| SCHEMBL12964930 | 0.78 | NOD1 (0.53) | DPP4DPP8DPP9GLP1RGLO1 | |
| SCHEMBL12964824 | 0.78 | NOD1 (0.53) | DPP4DPP8DPP9GLP1RGLO1 | |
| SCHEMBL16421659 | 0.77 | DPP4 (0.49) | DPP4DPP8DPP9GLO1CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570178-B2 | Selective delivery molecules and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570178-B2 | Selective delivery molecules and methods of use | SLC7A1, SLC47A1, SLC47A2 | DPP4 3161/4885DPP8 1778/4885DPP9 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.